Research
Macro partitioning
Anti-obesity medications (AOMs) cause disproportionate loss of lean mass (skeletal muscle), which may worsen frailty and functional capacity in heart failure patients, necessitating concurrent resistance training and protein intake.
When using GLP-1 or GLP-1/GIP medications for heart failure, be aware that you will lose muscle mass along with fat. To protect your strength and function, you MUST combine these medications with resistance training and ensure adequate protein intake. Monitor your functional capacity closely.
GoodRefutesHIGH confidence
Studies suggest that significant portions of the weight lost with GLP-1 RAs and dual agonists may involve fat-free mass (FFM)... Tirzepatide resulted in a greater FFM loss compared to placebo (− 1.5 kg; 95% CI: −2.3 to − 0.7; P < 0.001)... Concerns have also been raised about potential adverse effects, such as the disproportionate loss of lean mass, which could impair functional capacity and possibly worsen frailty in vulnerable individuals
Why this rating
Based on comparative studies cited in the review.
Source
The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review
Pamela L. Alebna et al. · Current Cardiology Reports · 2025
narrative_reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →